Oral Vaccine Market Size to Surpass USD 9.62 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID-19 Impact on Oral Vaccine Market

5.1. COVID-19 Landscape: Oral Vaccine Industry Impact

5.2. COVID-19 - Impact Assessment for the Industry

5.3. COVID-19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Oral Vaccine Market, By Vaccines Type

8.1. Oral Vaccine Market Revenue and Volume Forecast, by Vaccines Type

8.1.1. Live Attenuated Vaccines

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Inactivated Vaccines

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Subunit Vaccines

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Others

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Oral Vaccine Market, By Application

9.1. Oral Vaccine Market Revenue and Volume Forecast, by Application

9.1.1. Infectious Diseases

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Cancer

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Others

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Oral Vaccine Market, By Distribution Channel

10.1. Oral Vaccine Market Revenue and Volume Forecast, by Distribution Channel

10.1.1. Hospital

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Clinics

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Oral Vaccine Market, By End-User

11.1. Oral Vaccine Market Revenue and Volume Forecast, by End-User

11.1.1. Paediatrics

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Adults

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Geriatrics

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Oral Vaccine Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Vaccines Type

12.1.2. Market Revenue and Volume Forecast, by Application

12.1.3. Market Revenue and Volume Forecast, by Distribution Channel

12.1.4. Market Revenue and Volume Forecast, by End-User

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Vaccines Type

12.1.5.2. Market Revenue and Volume Forecast, by Application

12.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5.4. Market Revenue and Volume Forecast, by End-User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Vaccines Type

12.1.6.2. Market Revenue and Volume Forecast, by Application

12.1.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6.4. Market Revenue and Volume Forecast, by End-User

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Vaccines Type

12.2.2. Market Revenue and Volume Forecast, by Application

12.2.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.4. Market Revenue and Volume Forecast, by End-User

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Vaccines Type

12.2.5.2. Market Revenue and Volume Forecast, by Application

12.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5.4. Market Revenue and Volume Forecast, by End-User

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Vaccines Type

12.2.6.2. Market Revenue and Volume Forecast, by Application

12.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6.4. Market Revenue and Volume Forecast, by End-User

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Vaccines Type

12.2.7.2. Market Revenue and Volume Forecast, by Application

12.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7.4. Market Revenue and Volume Forecast, by End-User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Vaccines Type

12.2.8.2. Market Revenue and Volume Forecast, by Application

12.2.8.3. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8.4. Market Revenue and Volume Forecast, by End-User

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Vaccines Type

12.3.2. Market Revenue and Volume Forecast, by Application

12.3.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.4. Market Revenue and Volume Forecast, by End-User

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Vaccines Type

12.3.5.2. Market Revenue and Volume Forecast, by Application

12.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5.4. Market Revenue and Volume Forecast, by End-User

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Vaccines Type

12.3.6.2. Market Revenue and Volume Forecast, by Application

12.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6.4. Market Revenue and Volume Forecast, by End-User

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Vaccines Type

12.3.7.2. Market Revenue and Volume Forecast, by Application

12.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7.4. Market Revenue and Volume Forecast, by End-User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Vaccines Type

12.3.8.2. Market Revenue and Volume Forecast, by Application

12.3.8.3. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8.4. Market Revenue and Volume Forecast, by End-User

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Vaccines Type

12.4.2. Market Revenue and Volume Forecast, by Application

12.4.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.4. Market Revenue and Volume Forecast, by End-User

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Vaccines Type

12.4.5.2. Market Revenue and Volume Forecast, by Application

12.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5.4. Market Revenue and Volume Forecast, by End-User

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Vaccines Type

12.4.6.2. Market Revenue and Volume Forecast, by Application

12.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6.4. Market Revenue and Volume Forecast, by End-User

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Vaccines Type

12.4.7.2. Market Revenue and Volume Forecast, by Application

12.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7.4. Market Revenue and Volume Forecast, by End-User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Vaccines Type

12.4.8.2. Market Revenue and Volume Forecast, by Application

12.4.8.3. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8.4. Market Revenue and Volume Forecast, by End-User

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Vaccines Type

12.5.2. Market Revenue and Volume Forecast, by Application

12.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.5.4. Market Revenue and Volume Forecast, by End-User

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Vaccines Type

12.5.5.2. Market Revenue and Volume Forecast, by Application

12.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5.4. Market Revenue and Volume Forecast, by End-User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Vaccines Type

12.5.6.2. Market Revenue and Volume Forecast, by Application

12.5.6.3. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6.4. Market Revenue and Volume Forecast, by End-User

Chapter 13. Company Profiles

13.1. Sanofi

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. GSK

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. IOS

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Takeda Pharmaceuticals

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Soligenix

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Liquidia Technologies

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Elasmogen

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Abivax

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Oravax Medical

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Rapid Dose Therapeutics

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global oral vaccine market size is expected to grow from USD 3.87 billion in 2024 to USD 9.62 billion by 2034.

The oral vaccine market is anticipated to grow at a CAGR of 9.53% between 2025 and 2034.

The major players operating in the oral vaccine market are Sanofi, GSK, IOS, Takeda Pharmaceuticals, Soligenix, Liquidia Technologies, Elasmogen, Abivax, Oravax Medical, Rapid Dose Therapeutics, AVRO Life Science, Prokarium Ltd, Matinas Biopharma, ACM Biolabs, Alcami, and Others.

The driving factors of the oral vaccine market is it attributable to the need for safer, easier-to-administrate, and more affordable vaccines than injectable vaccines.

North America region will lead the global oral vaccine market during the forecast period 2025 to 2034.